Showing results (1341-1350 of 1,689) with videos related to

Sort By:
Pageof 169
Lancet (London, England)|August 30, 2021
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trialJoAnn Lindenfeld, Michael R Zile, Akshay S Desai, et al.
Circulation|September 28, 2024
Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart FailureMuthiah Vaduganathan, Brian L Claggett, Ian J Kulac, et al.
Prostate Cancer and Prostatic Diseases|May 26, 2021
Inflammatory bowel disease induces inflammatory and pre-neoplastic changes in the prostateAnuj S Desai, Vinay Sagar, Barbara Lysy, et al.
Journal of the American Heart Association|November 19, 2021
Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HFLeanne Mooney, Nathaniel M Hawkins, Pardeep S Jhund, et al.
Circulation. Heart Failure|December 10, 2019
Sex-Related Differences in Heart Failure With Preserved Ejection FractionPooja Dewan, Rasmus Rørth, Valeria Raparelli, et al.
JAMA Cardiology|November 17, 2024
Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection FractionOrly Vardeny, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|February 5, 2026
Efficacy and Safety of the Kidney Function-Based Finerenone Dosing Strategy Used in FINEARTS-HFMisato Chimura, Alasdair D Henderson, Pardeep S Jhund, et al.
Circulation|October 13, 2023
Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER TrialJohn W Ostrominski, Muthiah Vaduganathan, Senthil Selvaraj, et al.
European Journal of Heart Failure|February 20, 2021
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trialJoão Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
Indian Journal of Cancer|June 21, 2014
ICON 2013: practical consensus recommendations for hormone receptor-positive Her2-negative advanced or metastatic breastcancerP M Parikh, S Gupta, S Dawood, et al.
Pageof 169